Could Taiwan's Next National Fortress Be Biomedicine? How AI-Powered Plant-Based Drugs Are Reshaping Preventive Medicine

Taiwan's biotechnology industry is at a pivotal turning point. As the population ages and chronic diseases and dementia become increasingly severe, is the traditional mindset of 'treating illness after it occurs' becoming outdated? Today, we welcome Wang Tian-di, Chairman of YaoTech Biotech, to exclusively analyze how Taiwan can build its next 'biomedical national fortress,' and uncover how advanced technologies such as plant stem cells and AI-powered multi-target gene sequencing are reshaping the future of health management.

While average life expectancy continues to rise, this does not necessarily mean people are living healthier lives. Preventive medicine will be the key to the future.

With rapid demographic aging, modern individuals are no longer just seeking longevity—they want to live healthily, with dignity and quality. Wang Tian-di points out that modern lifestyles, stress, dietary habits, and environmental burdens often keep the body in a chronically imbalanced state. As a result, health management is gradually shifting from past models of 'disease treatment' toward 'preventive medicine + precision healthcare.'

Future health management will no longer wait until symptoms appear before seeking treatment. Instead, through health screenings, lifestyle management, nutritional supplementation, and technological analysis, risks can be detected early and interventions initiated proactively. In an era defined by aging populations and the prevalence of chronic diseases, extending 'healthspan' will become the next major battleground for the global biotech and medical industry.

Alzheimer’s disease remains incurable—how can plant-based pharmaceuticals intervene earlier in health risks?

Alzheimer’s disease remains one of the most challenging issues in global medicine. Despite recent breakthroughs in drug development, current treatments still face limitations in applicable patient groups, efficacy, and cost. Wang explains that precisely because of these challenges, YaoTech Biotech has partnered with Guanxin Biomedicine to focus on preventive medicine and natural plant research. The goal is to use plant-derived ingredients combined with advanced technology to help maintain bodily balance and manage health risks before serious conditions develop.

The program also dives deep into YaoTech Biotech’s proprietary plant stem cell technology and AI-powered multi-target gene sequencing. By analyzing vast datasets of plant compounds alongside human genes and protein pathways, AI identifies the most promising combinations of botanical ingredients. Health management is thus moving beyond the outdated model of 'one-size-fits-all' supplements toward a more precise, personalized approach.

From plant extraction to pharmaceutical-grade production: Four core technologies shaping a new frontier in biomedicine

With countless health supplements available on the market, what truly defines a trustworthy health product? Wang emphasizes that the key lies not in brand reputation or ingredient count, but in robust scientific validation, rigorous R&D processes, and technological backing.

YaoTech Biotech integrates four core technologies: next-generation precision temperature-controlled supercritical CO₂ extraction, liposomal encapsulation, AI-powered multi-target gene sequencing, and next-generation synbiotic super-complex formulations. This integration aims to transcend the limitations of traditional supplements, which have long been seen as mere nutritional additives. Through precise extraction and AI-driven analysis of various plants, health management evolves from simple 'supplementation' to cellular-level support and regulation.

Challenging the FDA and targeting the Taiwan Innovation Board: How can Taiwan’s biotech industry go global?

Beyond R&D, how can Taiwan’s biotech industry move beyond the lab and reach global markets? This remains a critical challenge. Wang notes that while Taiwan possesses strong academic and R&D capabilities, many innovations struggle with commercialization and market integration.

Since 2011, YaoTech Biotech has been dedicated to plant-based drug development, accumulating a comprehensive plant database, targeted extraction techniques, an AI-powered multi-target gene sequencing platform, and human clinical data. The company is also actively expanding into international and capital markets. Applications to the FDA, filings with the Taiwan Innovation Board, and ambitions to list on Nasdaq represent not just corporate strategy—but a long-term vision to showcase Taiwan’s biotech innovation on the world stage.